Technology Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858… AIT News Desk Dec 14, 2022 Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2)…
Machine Learning Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology… AIT News Desk Dec 14, 2022 Partnership brings Iterative Health’s AI Recruitment technology to Gastro Health to help identify patients for clinical trials Iterative…